Standalone sales for January 2026 increased 6.8% year-over-year. The Laboratory segment grew by 10.6%, Industry by 4.9%, and Medical declined by 4.1%.
Sales for December 2025 grew year-over-year in all three major sectors, resulting in an overall +9.0% increase year-over-year. The expansion of the EC channel contributed significantly.
For the third quarter of the fiscal year ending March 2026, consolidated net sales were 79.204 billion yen (5.1% increase YoY), operating income was 9.435 billion yen (12.4% increase YoY), and net income attributable to owners of the parent was 6.715 billion yen (12.4% increase YoY).
For the third quarter of the fiscal year ending March 2026, net sales reached 79,204 million yen (Year-over-Year +5.1%), operating income was 9,435 million yen (Year-over-Year +12.4%), and quarterly net income was 6,715 million yen (Year-over-Year +12.4%), all marking record highs.